Share Forum - Discuss JSE shares and join the Investor Challenge

Difficult question. AG Global is almost at the very bottom in its sector of +- 380 funds performance wise. Prior to 2014, it performed at around 30% pa so it might be a gamble to sell now.

Not yet as I'm waiting for the Portuguese IRS tax exemption.

The INDI has woken from its slumber. Broke through the resistance line some days ago and this uptrend was confirmed by the MACD crossover.

you mean APN. not ASP. 

Britain’s biggest drugmaker will remain a 6.2% shareholder in Aspen and has undertaken not to sell any more shares in the South African group for 180 days.

  I already bought @ R440 per share. But will be keeping it, as their previous results was good. When to buy I suppose is up to you, I have noticed that APN is in the Top traded by value list, where it was not usually.

LONDON — GlaxoSmithKline has taken profits in Aspen Pharmacare by selling half its stake in the South African drugmaker for $853m, following a long investment in the firm.

The sale, which was conducted through a share placing at a discount to the market price, is the latest example of GSK pruning non-core investments as it refocuses its business and works to protect its sizeable dividend payments to shareholders.

Britain’s biggest drugmaker will remain a 6.2% shareholder in Aspen and has undertaken not to sell any more shares in the South African group for 180 days.

GSK said on Friday it had sold 28.2-million Aspen shares at R372 each, compared to Thursday’s closing price of 406.5.

The sale was handled by Citi and UBS.

In November 2013, GSK sold another similar sized tranche of Aspen stock for R250 a share.

Simon Dingemans, GSK’s chief financial officer, said the disposal would help give his company flexibility to invest in new opportunities in the wake of a $20bn-plus asset swap transaction with Novartis.

"As we continue to reshape the group around our core franchises and drive the benefits from the Novartis transaction, optimising our financial flexibility to invest behind these priorities is key," he said in a statement.

"As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future."

GSK said that the net profit on the disposal would not be included in core operating profit and core earnings in 2015, and GSK would no longer account for Aspen as an associate.

However, the British group’s head of strategy, David Redfern, who was recently appointed as GSK’s nominee director on Aspen’s board to replace GSK president of pharmaceuticals Abbas Hussain, will remain a director, Aspen said.

GSK has been suffering from weak sales of its key respiratory drugs in the past year, especially in the US, and has implemented a £1bn cost-cutting programme.

It is also considering an initial public offering for its majority-owned HIV unit, known as ViiV Healthcare. But plans to sell a portfolio of older drugs were dropped in December

 

INTERNATIONAL BUSINESS

Revenue in the International business was 158% higher at R8.8 billion and performance was boosted by the inclusion of the significant transactions completed during the previous financial year.

Revenue from the Europe CIS business climbed 229% to R5.1 billion from finished dose form pharmaceuticals and active pharmaceutical ingredient sales.

Revenue in Latin America advanced 118% to R2.6 billion, largely driven by the recent infant milk formula acquisition, while sales to customers in the Rest of the World were up 36% to R0.9 billion.

Capital expenditure projects are continuing at Aspen Oss in the Netherlands and at the French-based Aspen Notre Dame de Bondeville site.

ASIA PACIFIC BUSINESS

Revenue in the Asia Pacific region was 3% higher at R4.4 billion where the Nutritionals products led the way with strong double-digit growth. Sales to customers in Asia continued on an impressive growth trajectory, doubling to R0.6 billion.

SOUTH AFRICAN BUSINESS

As the ongoing leading pharmaceutical manufacturer in the country, revenue in the South African business grew by 12% to R4.3 billion. Private sector pharmaceutical sales increased 10% through a combination of organic growth and new product launches. Sales in the public sector were flat. The consumer division raised revenue by 30%, led by the Nutritionals products with Infacare achieving an increase in its share of this category.

The capital expenditure projects at the Port Elizabeth finished dose form manufacturing site and the Cape Town API manufacturing site are progressing well.

SUB-SAHARAN BUSINESS

In Sub-Saharan Africa, revenue improved by 5% to R1.5 billion. Margin improvement initiatives yielded positive results and lifted EBITA 12% to R210 million.